Clin Neurophysiol. 2016 Nov 2;128(1):93-99. doi: 10.1016/j.clinph.2016.10.088. [Epub ahead of print]
To explore the benefits of modified-release fampridine on walking distance in MS.Methods
This was a randomised double-blind, placebo-controlled crossover trial of fampridine in 25 MS patients. The primary outcome measure was the six minute walk test (6MWT). A p-value < 10% led to rejection of the null hypothesis.
ResultsThe pre-specified criterion for statistical significance was met, with a 17 m improvement in 6MWT in the treatment arm. In addition, baseline S2 accommodation, a nerve excitability parameter that reflects slow K+ channel activity, modified the effect of fampridine. For patients who had abnormally high S2 accommodation values, there was a 28 m improvement in the 6MWT (p = 0.04). In contrast, for patients with low S2 values, a 0 m improvement was noted (p = 1.0).
ConclusionThe study provides evidence that fampridine may improve walking distance. Nerve excitability assessment may be useful in selecting those patients who are most likely to gain benefit from fampridine.
SignificanceFampridine may improve walking distance in MS. Nerve excitability assessment may assist in identifying those patients most likely to respond to fampridine.